Antibody Partnering Terms and Agreements

Published: December 2013
No. of Pages: 1895
  

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,100 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibody deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2007.

In addition, a comprehensive appendix is provided organized by antibody partnering company A-Z ,deal type, stage of development type and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

Report scope

Antibody Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

Antibody Partnering Terms and Agreements includes:

  • Trends in antibody dealmaking in the biopharma industry since 2007
  • Analysis of antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibody deals
  • Access to over 1,100 antibody contract documents
  • The leading antibody deals by value since 2007
  • Most active antibody dealmakers since 2007
  • The leading antibody partnering resources

In Antibody Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Antibody Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,100 antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Benefits

Antibody Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of antibody deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of antibody agreements with numerous real life case studies
  • Comprehensive access to over 1100 actual antibody deals entered into by the world’s biopharma companies
  • Detailed access to actual antibody contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Antibody Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in antibody dealmaking
2.1. Introduction
2.2. Antibody partnering over the years
2.3. Bigpharma antibody dealmaking activity
2.4 Big Biotech antibody dealmaking activity
2.5. Top 10 active antibody dealmakers
2.6. Antibody partnering by deal type
2.7. Antibody partnering by disease type
2.8. Partnering by antibody type
2.9. Average deal terms for antibody partnering
2.9.1 Antibody headline values
2.9.2 Antibody upfront payments
2.9.3 Antibody milestone payments
2.9.4 Antibody royalty rates
2.10. The anatomy of antibody partnering
2.10. The anatomy of an antibody deal
2.10.a. Case study 1: ADMA Biologics- Biotest: December 31 2012
2.10.b. Case study 2: Amgen- AstraZeneca: April 2, 2012

Chapter 3 – Leading antibody deals
3.1. Introduction
3.2. Top antibody deals by value

Chapter 4 –Big pharma antibody deals
4.1. Introduction
4.2. How to use bigpharma antibody partnering deals
4.3. Big pharma antibody partnering company profiles
Abbott
Actavis Inc (formerly Watson Pharmaceuticals)
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Eisai
Eli Lilly
Endo Pharmaceuticals
Gilead Sciences
GlaxoSmithKline
Grifols
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
UCB
Watson

Chapter 5 – Leading big biotech antibody deals
5.1. Introduction
5.2. How to use bigbiotech partnering deals
5.3. Bigbiotech antibody partnering company profiles
Alexion Pharmaceuticals
Amgen
Biocon
Biogen Idec
Celgene
CSL
Elan
Emergent BioSolutions
Genmab
Gilead Sciences
Immunomedics
Morphosys
PDL BioPharma
Regeneron Pharmaceuticals
Roche
Seattle Genetics
Spectrum Pharmaceuticals
UCB

Chapter 6 – Antibody dealmaking directory
6.1. Introduction
6.2. By Company A-Z
3M
AaiPharma
Abbott Laboratories
Adimab
ADMA Biologics
Agensys
Alexion Pharmaceuticals
Allphase Clinical Research Services
Amgen
Arana Therapeutics
Astellas
AstraZeneca
Avanir Pharmaceuticals
Avecia Biologics
Aventis
AVEO Pharmaceuticals
Bayer
Bayer Schering Pharma
Biogen Idec
Biotest
Biotest Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Research Technology
CancerVax
Cell-Matrix
Cell Therapeutics
Celldex Therapeutics
Cellectis
Centocor Ortho Biotech
CIMAB SA
Cimym
Corgenix Medical
Crucell
Cytodyn
Daiichi Sankyo
Dyax
Elan
Emergent BioSolutions
Facet Biotechnology
GE Healthcare
Genentech
Genmab
Genzyme
GlaxoSmithKline
GlycArt
GTC Biotherapeutics
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Intellect Neurosciences
Janssen Pharmaceutica NV
Johnson & Johnson
Kaketsuken
KaloBios
Lexicon Pharmaceuticals
LFB Biotechnologies
Lonza
Lpath
Massachusetts Biologic Laboratories
Matsuura
Medarex
MedImmune
Merck and Co
Merck Serono
Merrimack Pharmaceuticals
Micromet
Millennium
Molecular Discoveries
MRC Technology
National Institute of Allergy and Infectious Diseases
Novo Nordisk
Nycomed
Oklahoma Medical Research Foundation
Oncoscience AG
Orbimed Advisors
Organon
Ortho-McNeil
PDL BioPharma
Percipio Biotherapeutics
Peregrine Pharmaceuticals
Pfizer
PharmAthene
Progenics Pharmaceuticals
Public Health Service
Regeneron Pharmaceuticals
Repligen
RIT Oncology
Roche
Sanofi-Aventis
Sanofi-Pasteur
Schering-Plough
Scripps Research Institute
Seattle Genetics
Serono
Servier
Sorrento Therapeutics
Spectrum Pharmaceuticals
Stason Pharmaceuticals
Takeda Pharmaceutical
Targepeutics
TRACON Pharmaceuticals
UCB
University of Southampton
University of Texas
Vista Biologicals
Wyeth
Xoma
YM BioSciences
ZymoGenetics
6.3. By stage of development
Discovery
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Co-promotion
Cross-licensing
Development
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Royalty financing
Settlement
Supply
Termination
6.5. By therapy area
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Hematology
Immunology
Infectives
Musculoskeletal
Oncology
Ophthalmics
Respiratory

Chapter 7 – By antibody type
7.1. Introduction
7.2. Deals by antibody type
Antibodies
Antibody-drug conjugate
Polyclonal antibodies

Chapter 8 – Antibody partnering resources
8.1. Online antibody partnering
8.2. Antibody partnering events
8.3. Further reading on antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List  of Figures

Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2007
Figure 3: Bigpharma – top 50 – antibody deals 2007 to 2013
Figure 4: Bigpharma antibody deal frequency – 2007 to 2013
Figure 5: Big biotech antibody deal frequency – 2007 to 2013
Figure 6: To 10 antibody dealmakers– 2007 to 2013
Figure 7: Antibody partnering by deal type since 2007
Figure 8: Antibody partnering by disease type since 2007
Figure 9: Antibody partnering by oncology target since 2007
Figure 10: Antibody partnering by therapeutic antibody type since 2007
Figure 11: Antibody deals with a headline value
Figure 12: Antibody deal headline value distribution, US$million – discovery stage
Figure 13: Antibody deal headline value distribution, US$million – preclinical stage
Figure 14: Antibody deal headline value distribution, US$million – phase I stage
Figure 15: Antibody deal headline value distribution, US$million – phase II stage
Figure 16: Antibody deal headline value distribution, US$million – phase III stage
Figure 17: Antibody deal headline value distribution, US$million – regulatory stage
Figure 18: Antibody deal headline value distribution, US$million – marketed stage
Figure 19: Summary median headline value by stage of development, 2007-2013
Figure 20: Antibody deals with upfront payment values
Figure 21: Antibody deal upfront payment distribution, US$million – discovery stage
Figure 22: Antibody deal upfront payment distribution, US$million – preclinical stage
Figure 23: Antibody deal upfront payment distribution, US$million – phase I stage
Figure 24: Antibody deal upfront payment distribution, US$million – phase II stage
Figure 25: Antibody deal upfront payment distribution, US$million – phase III stage
Figure 26: Antibody deal upfront payment distribution, US$million – regulatory stage
Figure 27: Antibody deal upfront payment distribution, US$million – marketed stage
Figure 28: Summary median upfront payments by stage of development, 2007-2013
Figure 29: Antibody deals with milestone payments
Figure 30: Antibody deal milestone distribution, US$million – discovery stage
Figure 31: Antibody deal milestone distribution, US$million – preclinical stage
Figure 32: Antibody deal milestone distribution, US$million – phase I stage
Figure 33: Antibody deal milestone distribution, US$million – phase II stage
Figure 34: Antibody deal milestone distribution, US$million – phase III stage
Figure 35: Antibody deal milestone distribution, US$million – regulatory stage
Figure 36: Antibody deal milestone distribution, US$million – marketed stage
Figure 37: Antibody deals with royalty rates, %
Figure 38: Antibody deal royalty rate distribution, US$million – discovery stage
Figure 39: Antibody deal royalty rate distribution, US$million – preclinical stage
Figure 40: Antibody deal royalty rate distribution, US$million – phase I stage
Figure 41: Antibody deal royalty rate distribution, US$million – phase II stage
Figure 42: Antibody deal royalty rate distribution, US$million – phase III stage
Figure 43: Antibody deal royalty rate distribution, US$million – regulatory stage
Figure 44: Antibody deal royalty rate distribution, US$million – marketed stage
Figure 45: Summary median royalty rate by stage of development, 2007-2013
Figure 46: Components of the typical antibody deal structure
Figure 47: Top antibody deals by value since 2007
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering30


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Personalized Medicine Partnering Terms and Agreements

    Comprehensive understanding and unprecedented access tthe personalized medicine partnering deals and agreements entered intby the worlds leading healthcare companies.The Personalized Medicine Partnering Terms and Agreements report pro...

  • Biomarker Partnering Terms and Agreements

    The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in bioma...

  • Companion Diagnostics Partnering Terms & Agreements

    The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe companion diagnostics partnering deals and agreements entered intby the worlds leading healthcare companies....

  • Vaccine Partnering Terms and Agreements

    The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in vaccine a...

  • Diagnostics Partnering Terms and Agreements

    The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detai...

  • Oncology Partnering Terms and Agreements

    On Demand reports are delivered in PDF by email within 1-3 business daysThe Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and ...

  • Bioinformatics Partnering Terms and Agreements

    The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Discovery Stage Partnering Terms and Agreements

    The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare com...


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Healthcare market as per your needs. Get the best of Healthcare research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100